Alembic Pharmaceuticals Ltd (APLLTD):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Alembic Pharmaceuticals Ltd (APLLTD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3334
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Alembic Pharmaceuticals Ltd (APL) is a pharmaceutical company which manufactures and markets generic pharmaceutical products. The company’s active pharmaceutical ingredients include macrolides, NSAIDs, and other drugs. It also offers branded formulations in the areas of antibiotics and antibacterial, cardiovascular, gynecological, cough and cold, gastroenterological, ophthalmological, anti-diabetic, orthopedic, urology, antihistamine, dermatological and herbal nutraceuticals. APL provides generic formulations such as anti-allergic, anthelmintic, antimicrobials, antiulcerants, nutritional and vitamin preparations, and others speciality products. The company has its research centres and manufacturing facilities in Vadodara, Gujarat and Baddi. APL is headquartered in Vadodara, Gujarat, India.

Alembic Pharmaceuticals Ltd (APLLTD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Alembic Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Alembic Pharma to Form Joint Venture with Orbicular Pharma 11
TG Therapeutics Enters Into Agreement With Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 12
Licensing Agreements 14
Novartis Enters into Licensing Agreement with Rhizen Pharma 14
TG Therapeutics Exercises Option for Licensing Agreement with Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 15
Ranbaxy Pharma Enters Into Licensing Agreement With Alembic Pharma For Desvenlafaxine Base Extended-Release Tablets 16
Accu-Break Pharma Enters Into Licensing Agreement With Alembic Pharma To Develop Novel Pharma Products 17
Asset Transactions 18
Alembic Pharma Sells its Formulations Manufacturing Facility to Scott-Edil Pharmacia 18
Acquisition 19
Alembic Pharma Acquires Orit Labs 19
Alembic Pharma to Acquire 49% Stake in Adwiya Mami 20
Alembic Pharmaceuticals Ltd – Key Competitors 21
Alembic Pharmaceuticals Ltd – Key Employees 22
Alembic Pharmaceuticals Ltd – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 25
Financial Announcements 25
Jul 20, 2017: Alembic Pharmaceuticals: QI Net Revenue at Rs 648 Crores, Net Profit at Rs 65 Crores 25
May 03, 2017: Alembic Pharmaceuticals: Q4 Net Revenue grew 18% to Rs 740 Crores, Net Profit at Rs 94 cr 27
Jan 25, 2017: Alembic Pharmaceuticals: Q3 Net Profit at Rs 86 cr, Net Revenues at Rs 776 cr 28
Legal and Regulatory 29
Jun 15, 2018: Alembic Pharmaceuticals Receives Establishment Inspection Report For Its Formulation Facility At Panelav 29
May 18, 2018: Alembic Pharmaceuticals Provides Update on US FDA Inspection At its API Facility At Karkhadi 30
Apr 24, 2018: Alembic Pharmaceuticals: Update on Successful US FDA Inspection API Facility at Panelav 31
Mar 21, 2018: USFDA Inspection Formulation Facility at Panelav 32
Aug 31, 2017: Alembic Pharmaceuticals Receives EU GMP Certificate For Its Formulation Facility At Panelav 33
Mar 10, 2017: Alembic Pharmaceuticals Announces US FDA Inspection at Baroda Facility 34
Government and Public Interest 35
Apr 17, 2017: Successful US FDA Inspection at Alembic Pharmaceuticals Bioequivalence Facility at Baroda 35
Other Significant Developments 36
Aug 18, 2017: Alembic Pharmaceuticals: Disruption in plant operations at Algerian JV 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alembic Pharmaceuticals Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Alembic Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Alembic Pharma to Form Joint Venture with Orbicular Pharma 11
TG Therapeutics Enters Into Agreement With Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 12
Novartis Enters into Licensing Agreement with Rhizen Pharma 14
TG Therapeutics Exercises Option for Licensing Agreement with Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 15
Ranbaxy Pharma Enters Into Licensing Agreement With Alembic Pharma For Desvenlafaxine Base Extended-Release Tablets 16
Accu-Break Pharma Enters Into Licensing Agreement With Alembic Pharma To Develop Novel Pharma Products 17
Alembic Pharma Sells its Formulations Manufacturing Facility to Scott-Edil Pharmacia 18
Alembic Pharma Acquires Orit Labs 19
Alembic Pharma to Acquire 49% Stake in Adwiya Mami 20
Alembic Pharmaceuticals Ltd, Key Competitors 21
Alembic Pharmaceuticals Ltd, Key Employees 22
Alembic Pharmaceuticals Ltd, Other Locations 23
Alembic Pharmaceuticals Ltd, Subsidiaries 23

List of Figures
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Alembic Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Alembic Pharmaceuticals Ltd (APLLTD):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • American Shared Hospital Services (AMS)-医療機器分野:企業M&A・提携分析
    Summary American Shared Hospital Services (ASHS) is a healthcare company that offers medical equipment to hospitals and medical centers. The company offers financial and healthcare tech solutions. Its financing solutions comprise feasibility studies and reimbursement analysis, facilities planning an …
  • Evoqua Water Technologies Corp (AQUA):企業の財務・戦略的SWOT分析
    Evoqua Water Technologies Corp (AQUA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Adamis Pharmaceuticals Corporation:企業のM&A・事業提携・投資動向
    Adamis Pharmaceuticals Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Adamis Pharmaceuticals Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on m …
  • RadiSys Corp (RSYS):企業の財務・戦略的SWOT分析
    Summary RadiSys Corp (RadiSys) is a provider of communication services. The company offers products include mobility engine, mediaengine, dcengine and embedded Products. It offers contact support, serviceengine, conceptualization, software customization, network design and integration; testing and a …
  • Petrol dd Ljubljana (PETG):企業の財務・戦略的SWOT分析
    Petrol dd Ljubljana (PETG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Velvet Energy Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Velvet Energy Ltd (Velvet Energy) is an oil and gas exploration company that explores and develops oil and liquid-rich natural gas from its assets. The company’s exploration and development operation assets are located in Deep Basin in West-Central Alberta. It produces 17,000 barrels of oil …
  • Massachusetts General Hospital:医療機器:M&Aディール及び事業提携情報
    Summary Massachusetts General Hospital (MGH) is a healthcare service provider which offers research, education and therapeutic care services. The hospital provides treatment and patient care services in the therapeutic areas of allergy and immunology; hematology, orthopaedics, neurology and neurosur …
  • Avid Technology Inc (AVID):企業の財務・戦略的SWOT分析
    Avid Technology Inc (AVID) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Fairfax Media Limited:企業の戦略・SWOT・財務情報
    Fairfax Media Limited - Strategy, SWOT and Corporate Finance Report Summary Fairfax Media Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Great Wall Motor Co Ltd:企業の戦略・SWOT・財務分析
    Great Wall Motor Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Great Wall Motor Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Dominion Energy Inc (D):企業の財務・戦略的SWOT分析
    Dominion Energy Inc (D) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • NextEra Energy Resources LLC-エネルギー分野:企業M&A・提携分析
    Summary NextEra Energy Resources, LLC (NEER), a subsidiary of NextEra Energy, Inc., is a diversified clean energy company and is one of the largest wholesale generators of electric power in the US. The company, together with its subsidiaries owns, develops, constructs, manages and operates electrici …
  • Biotest AG (BIO):製薬・医療:M&Aディール及び事業提携情報
    Summary Biotest AG (Biotest) provides pharmaceutical and biotherapeutic drugs. It develops, manufactures and distributes biological medicines through its value chain from preclinical and clinical development to sales. Its main products comprise clotting factors, immunoglobulins, albumin and monoclon …
  • Tsakos Energy Navigation Ltd (TNP):石油・ガス:M&Aディール及び事業提携情報
    Summary Tsakos Energy Navigation Ltd (TEN), a subsidiary of Tsakos Group, is a marine transportation company that provides transportation services of crude oil, petroleum products and liquefied natural gas (LNG) to national and international oil companies and refineries. It charges customer on time …
  • Citla Energy SAPI de CV:石油・ガス:M&Aディール及び事業提携情報
    Summary Citla Energy SAPI de CV (Citla Energy) is an oil and gas company that offers crude oil and natural gas exploration and production services. The company acquires and builds a portfolio of selected onshore and offshore assets independently and with other industry participants. It also provides …
  • Leclanche SA (LECN):企業の財務・戦略的SWOT分析
    Leclanche SA (LECN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Sunoco LP (SUN):石油・ガス:M&Aディール及び事業提携情報
    Summary Sunoco LP (Sunoco), a master limited partnership company that sells motor fuels in retail and wholesale channels. It offers motor fuel under brands such as Sunoco, Citgo, Chevron, Conoco, Aloha, Exxon, Mahalo, Mobil, Phillips 66, Texaco, Shell, Shamrock and Valero. The company operates throu …
  • InfuSystem Holdings Inc (INFU):企業の財務・戦略的SWOT分析
    Summary InfuSystem Holdings Inc (InfuSystem) is a provider of infusion pumps and related services. The company provides ambulatory infusion pumps and associated clinical services. Its patient services comprise infucare help hotline, infuease, education, and pain management. InfuSystem offers pumps a …
  • MSC Crociere S.A.:企業の戦略・SWOT・財務情報
    MSC Crociere S.A. - Strategy, SWOT and Corporate Finance Report Summary MSC Crociere S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Strongbridge Biopharma plc (SBBP):企業の財務・戦略的SWOT分析
    Summary Strongbridge Biopharma plc (Strongbridge) formerly Cortendo Plc, is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases. The company’s marketed product KEVEYIS (dichlorphenamide) is indicated for the treatment of hypokalemic, hyperkalemic …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆